Search results
Added:
1 year ago
In this short interview, Dr Joan Carles Trullas (Universitat de Vic-Central de Catalunya, ES) outlines the findings of the CLOROTIC trial, first presented at Heart Failure 2022.In this study, patients with decompensated heart failure were given a combined diuretic therapy using loop diuretics with thiazide diuretics to evaluate efficacy.
Discussion Points:
1. Background
2. Patient Cohort and…
View more
Added:
1 year ago
SC Congress 22 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sat down with the principal investigator of the ADVOR trial (NCT03505788), Prof Wilfried Mullens (Hospital Oost-Limburg (ZOL), BE) to talk about the trial design and practical consideration in light of the new data.
ADVOR, a multi-center, randomized, double-blind clinical trial assessed the diuretic effects of…
View more
Added:
11 months ago
ESC-HFA 2023 – Prof John Cleland (University of Glasgow, Glasgow, UK) discusses the findings from a study that looked at the diagnostic of heart failure in a cohort of 1.1 million people using the NHS EMR database.
Finding presented at Heart Failure 2023, showed that more people treated with LD than receive diagnosis of heart failure, this disparity was greater in women compared to men.
…
View more
Added:
3 years ago
In the US, 90% of the one million annual hospitalizations for heart failure (HF) are due to volume overload.1,2 Hypervolemia contributes to HF progression and mortality. Guidelines recommend that therapy for HF patients be aimed at achieving euvolemia. Intravenous loop diuretics induce rapid diuresis that reduces lung congestion and dyspnea. However, the effectiveness of loop diuretics declines…
View more
Added:
3 years ago
Chronic heart failure (CHF) is a major public health problem in industrialized societies, with an incidence approaching 10 per 1,000 population after age 65 and an age-dependent prevalence of less than 1% between ages 45 and 55, 2-5% between ages 65 and 75, and approximately 10% for patients aged 80 years or more.1-3 Thus, HF is primarily a condition of the elderly, and approximately 80% of…
View more
Added:
11 months ago
ESC-HFA 2023 — Dr Jasper Brugts (Thoraxcenter, NL) joins us to outline the findings and summarise the take-home messages from the MONITOR-HF trial (NTR7672).
MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation, irrespective of…
View more
Added:
3 years ago
Volume Overload in Heart Failure
The burden of heart failure (HF) remains formidable in the US, with nearly one million annual hospital admissions and frequent outpatient visits to a variety of care providers.1 While HF outcomes have improved modestly over the past several decades, many patients still struggle to maintain a satisfactory quality of life.2 Implantable cardioverter–defibrillators…
View more
Added:
3 years ago
Acute decompensated heart failure (ADHF) is a syndrome defined by worsening fatigue, dyspnea, or edema that results from deteriorating heart function and usually leads to hospital admission or unscheduled medical intervention.1 Among patients over 65 years of age it remains the leading cause of hospital admission (>1 million admissions per year in the US alone), has an exceptionally high rate…
View more
Added:
3 years ago
Chronic heart failure (CHF) is a major public health problem in industrialized societies with an incidence approaching 10 per 1,000 population after age 65 and an age-dependent prevalence of less than 1% between ages 45-55, 2-5% between ages 65-75, and approximately 10% for patients aged 80 years or more.Thus, HF is primarily a condition of the elderly and approximately 80% of patients…
View more
Added:
11 months ago
ESC-HFA 23 — Dr Stephen Greene (Duke University School of Medicine, US) outlines the findings from the QoL study of the TRANSFORM-HF Trial (NCT03296813).
The TRANSFORM-HF trial is a randomized trial which compared torsemide to furosemide as a treatment for patients with heart failure. Around 2859 patients with heart failure were enrolled in the trial, whose clinical outcomes were measured across…
View more
